Press Release Details

Cerus and Grifols to Collaborate on INTERCEPT Red Cell Kit Development

June, 02 2009

CONCORD, Calif. & BARCELONA, Spain -- Cerus Corporation (NASDAQ:CERS) and a subsidiary of Grifols S.A. (MCE:GRF) today announced that the two companies have entered into an agreement to collaborate on the development of red blood cell treatment sets for use in the INTERCEPT Blood System. The agreement calls for Laboratorios Grifols to provide their technical expertise and resources for the development of commercial kit manufacturing, and also establishes the parties' joint commitment to a future commercial manufacturing contract. The INTERCEPT red blood cell system, currently in Phase I trials, is being developed to inactivate a broad range of pathogens that may contaminate donated blood.

"Grifols' demonstrated expertise in blood collection sets is a significant asset to the INTERCEPT red cell program," said Claes Glassell, president and CEO of Cerus Corporation. "Building on our collaboration with the German Red Cross (DRK Frankfurt) to support system validations and clinical trial planning in Europe, these two collaborations are critical to support continued development of our red cell program."

Grifols has been a distributor of the INTERCEPT Blood System for platelets and plasma since 2007. Their current territory includes Spain, Portugal, Italy and Chile.

"We are pleased to further strengthen our relationship with Cerus after our success with the INTERCEPT platelet system," added Albert Grifols, general manager of Laboratorios Grifols.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The INTERCEPT red blood cell system is currently in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

ABOUT GRIFOLS

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Continuous Market and forms part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments and those which will be carried out in 2008-2012, representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply with 80 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.

The statements in "About Cerus" are made solely by Cerus, and the statements in "About Grifols" are made solely by Grifols.

Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding the clinical development and commercialization of the INTERCEPT Blood System for red blood cells. Because these forward-looking statements are subject to risks and uncertainties, actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks and uncertainties involving commercial adoption and market acceptance of the INTERCEPT Blood System, as well as other risks and uncertainties disclosed from time to time in reports filed by Cerus with the Securities and Exchange Commission, including Cerus' quarterly report on Form 10-Q the quarter ended March 31, 2009. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600